Nicola Dalbeth

After earning a medical degree at the University of Otago, and training at Oxford University and Imperial College London she moved to the University of Auckland, rising to full professor.[1][2] In 2019, Dalbeth was elected a Fellow of the Royal Society of New Zealand.[3]

Much of Dalbeth's research focuses on gout, a chronic disease of monosodium urate crystal deposition.[4]

• Khanna, Dinesh, John D. Fitzgerald, Puja P. Khanna, Sangmee Bae, Manjit K. Singh, Tuhina Neogi, Michael H. Pillinger et al. "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia." Arthritis care & research 64, no. 10 (2012): 1431-1446.
• Khanna, Dinesh, Puja P. Khanna, John D. Fitzgerald, Manjit K. Singh, Sangmee Bae, Tuhina Neogi, Michael H. Pillinger et al. "2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis." Arthritis care & research 64, no. 10 (2012): 1447-1461.
• Neogi, Tuhina, Tim L. Th A. Jansen, Nicola Dalbeth, Jaap Fransen, H. Ralph Schumacher, Dianne Berendsen, Melanie Brown et al. "2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative." Arthritis & rheumatology 67, no. 10 (2015): 2557-2568.
• Dalbeth, Nicola, Roger Gundle, Robert JO Davies, YC Gary Lee, Andrew J. McMichael, and Margaret FC Callan. "CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation." The Journal of Immunology 173, no. 10 (2004): 6418-6426.
• Dalbeth, Nicola, Sunil Kumar, Lisa Stamp, and Peter Gow. "Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout." The Journal of Rheumatology 33, no. 8 (2006): 1646-1650.